Objectives. Our aim is to add to the limited existing prospective data on IL-1 inhibitor use in pregnancy.
Introduction
Chronic autoimmune and auto-inflammatory conditions often affect young women of childbearing age, posing a dilemma during pregnancy, as these diseases frequently require the use of immune-modulating medications with unknown maternal and fetal consequences. While an increasing amount of data is emerging regarding the safety of more commonly used medications in pregnancy, there is still a dearth of data regarding the safety of anakinra, an IL-1 inhibitor used for febrile conditions such as systemic JIA and adult-onset Still's disease (AOSD), among others. The current recommendation by EULAR is to discontinue this medication prior to pregnancy given the lack of safety evidence [1] . This case series of five successful pregnancies on anakinra serves to add to the limited existing data on IL-1 inhibitor use in pregnancy.
Methods
Source of the sample Data were obtained from the Organization of Teratology Information Specialists (OTIS) Autoimmune Disease in Pregnancy Project, a prospective cohort study of pregnancy outcomes among women in the USA and Canada. Participants were recruited from pregnant callers to OTIS counselling services throughout the USA and Canada who initiated contact with an OTIS service with questions about any exposure in pregnancy, as well as by direct marketing to consumers through social media and the OTIS MotherToBaby study website. Participants were also recruited through direct marketing to medicine specialists such as rheumatologists, gastroenterologists, dermatologists, neurologists, obstetricians, nurses and other health care professionals through mail, professional meetings and the website. Pregnant women were enrolled in the cohort study between 2004 and 2017, and were considered eligible if they enrolled prior to 19 completed weeks' gestation and had not enrolled in this study with a previous pregnancy. This study was approved by the Institutional Review Board for the OTIS autoimmune diseases in pregnancy study at the University of California, San Diego. All women in the study provided oral consent for participation.
Study design and data collection
Women who consented to participate were interviewed by telephone two to three times during pregnancy using a standard questionnaire about their medical history, prescription and non-prescription medication exposures during pregnancy, history of previous pregnancies, family medical history, pre-pregnancy BMI, and socioeconomic and demographic characteristics of the woman and her partner. Exposure history included start and stop dates of each prescription and over-the-counter medication, as well as indications, dosage changes and frequencies, use of caffeine, dietary supplements, occupational exposures, infections, prenatal testing or other medical procedures and use of recreational drugs, tobacco and alcohol.
Birth outcomes were obtained using a standard interview form completed by telephone shortly after delivery. Women were asked about exposure information through the end of pregnancy, the presence or absence of major structural defects, gestational age at delivery, mode of delivery, length and type of hospital stay, maternal or newborn complications, maternal weight gain, and infant birth weight, length and head circumference.
Medical records from the prenatal care provider, delivery hospital, any specialty providers that managed the woman's care in pregnancy and the paediatrician were collected and data abstracted for additional exposure and outcome information, including validation of maternal self-report of autoimmune disease diagnosis. In addition, the infant's physician was asked to return a form reporting postnatal growth measures and the presence or absence of any major structural defects.
Results
A total of five pregnancies with anakinra exposure were identified. All pregnancies resulted in successful singleton live births. Baseline maternal characteristics for these five pregnancies are outlined in ). Three maternal subjects used anakinra for AOSD and two used the medication for systemic JIA. One maternal subject was diagnosed with AOSD during pregnancy, and anakinra was started at 20 weeks' gestation. All other subjects had a known diagnosis prior to pregnancy and four subjects used the medication into the third trimester.
All maternal subjects used 100 mg dosing of anakinra, four with daily use and one with weekly use. For each of the five subjects, when anakinra was discontinued, some amount of steroid medication was necessary for treatment. The first subject used anakinra through 20.4 weeks and required methylprednisolone at 22.3 weeks. The second subject, who was diagnosed with AOSD during pregnancy, required prednisone at disease onset (18.6 weeks). The corticosteroid was able to be discontinued at 27.6 weeks, while anakinra was used through 38.1 weeks. The third subject discontinued anakinra at 16.6 weeks and subsequently required highdose methylprednisolone at 19.1 through 19.7 weeks. Anakinra was restarted from 19.4 to 37.3 weeks' gestation, and the patient did not require any further corticosteroid treatment. The fourth subject discontinued anakinra at 2 weeks' gestation and then required prednisone at 3 weeks. Anakinra was restarted at 9.6 weeks, and corticosteroids were tapered off by 11.7 weeks' gestation. The last subject did not have any steroid use and was continued on anakinra from preconception through the third trimester ( Table 1) .
As far as additional exposures, the first subject was exposed to LEF 8.8 weeks prior to conception, and given a washout with cholestyramine 6 weeks prior to conception. This patient was also exposed to celecoxib, SSZ and HCQ during her pregnancy, the latter two after discontinuing anakinra at 20.4 weeks. The second subject had additional exposures of duloxetine, tobacco and alcohol. The third subject had a diagnosis of a hypercoagulable state and was continued on anticoagulation with enoxaparin throughout her pregnancy. There were no other significant exposures in the remaining subjects (Table 1) .
Maternal and fetal outcomes are outlined in Table 2 . All pregnancies were delivered at term with mean gestational age at delivery of 38.9 weeks (range 37.140.1 weeks). Two pregnancies had complications: the first subject developed pregnancy-induced hypertension and oligohydramnios, and the fifth subject developed oligohydramnios alone. Two of the five subjects had a Caesarian section, one medically indicated for pregnancy-induced hypertension and low fluid levels, and one previously scheduled. One infant had low birth weight. Postpartum data indicate that this infant had a normal adjusted weight by 4 months of age and through 1 year follow-up. The records for three of the five pregnancies indicate neonatal jaundice, but none was listed as having any major long-term complications or malformations. Three of the five women successfully breastfed their infant with no complications, at least two of whom continued anakinra while breastfeeding (postpartum exposure data were not available for the third subject).
Discussion
Our data from five successful pregnancies suggest that antenatal anakinra use is associated with less corticosteroid use and generally favourable maternal and fetal outcomes. Prior data on anakinra in pregnancy has also been reassuring. Youngstein et al. [2] analysed 43 pregnancies retrospectively, 23 of which were maternally exposed to anakinra. One single case of a congenital abnormality was identified (ectopic neurohypophysis with growth hormone deficiency and left renal agenesis) in an AOSD patient with active and refractory disease requiring high-dose corticosteroids. Ten neonates were breastfed by mothers taking anakinra for up to 10 months duration with no serious reported infections, and there were no developmental abnormalities noted in the infants, with a median followup time of 18 months. Another series focused on nine women with cryopyrinassociated periodic syndromes who became pregnant and continued anakinra throughout their pregnancies [3] . In this series, one patient on anakinra was induced for preeclampsia, but otherwise there were no adverse pregnancy outcomes and all infants were born at full term, with the exception of one fetal demise at 30 weeks in a twin dichorionic-diamniotic pregnancy due to renal agenesis. Seven additional cases of antenatal anakinra use in women with AOSD or FMF have been reported in the literature, all resulting in uncomplicated and successful pregnancies [47] .
Two of the five cases in our study developed oligohydramnios for reasons that are unclear. The first subject in our study with oligohydramnios had exposure throughout her pregnancy to celecoxib, a drug in the NSAID class that has been previously associated with the development of low amniotic fluid levels [8] . This patient also had a history of asthma and exposure to three other DMARDs, thereby complicating her clinical picture. However, given that the only two previously reported congenital abnormalities associated with maternal anakinra exposure are cases of fetal renal agenesis, a process that also may result in oligohydramnios, there is perhaps a potential connection between anakinra and maternal fluid levels that is worth further investigation. Interestingly, maternal fever and 'flulike illness have also been associated with a higher risk of congenital renal anomalies [9] . Since the diseases that are treated with anakinra tend to be febrile illnesses such as AOSD and systemic JIA, there may be a link between uncontrolled maternal disease and these renal anomalies. Indeed, one of the prior cases of renal agenesis and one of the cases of oligohydramnios in our study were both noted to be in the setting of uncontrolled maternal disease, further supporting this hypothesis. Anakinra use may have a somewhat protective effect on pregnancy outcomes for individuals with IL-1-driven disease. The miscarriage rate was 30% for pregnancies not on anakinra vs 10% for pregnancies on anakinra in the aforementioned cryopyrin-associated periodic syndromes study [3] . An additional study looking at murine models with an elevated IL-1 environment found that when these mice were given IL-1 inhibition, it prevented pregnancy loss [10] . A common theme among prior case exposures is flaring disease activity when taken off anakinra, but good response after the medication is restarted. This pattern of disease activity in relation to the medication, seen in both our study and prior studies, supports the use of the medication during pregnancy, especially when no alternative therapies are available to control disease.
Conclusion
Anakinra was used successfully in five pregnancies from the OTIS registry. All infants were born at full term with no serious complications or adverse outcomes. Pregnancies that discontinued anakinra had some degree of a disease flare requiring steroid therapy, implying that anakinra may be important for controlling disease activity during pregnancy and minimizing corticosteroid use. Two of the five maternal subjects developed oligohydramnios, although additional exposures for one of these pregnancies may have put the patient at elevated risk. However, given two previously reported cases of fetal renal agenesis, a process that also may lead to low fluid levels, as well as reports of maternal hyperthermia being related to congenital renal anomalies, it is worth exploring further a potential link between anakinra, fetal outcomes and maternal febrile disease activity. These data add to the limited knowledge regarding anakinra use in pregnancy and support its use to help achieve successful pregnancies for women who do not have alternative therapies with a larger volume of reassuring safety data at their disposal.
